Vivus Would Market Qnexa With Pregnancy Category X Designation If Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
With a strict REMS its only possible future, the weight-loss drug is unaffected by FDA decision to reclassify the topiramate portion of the combination drug as Pregnancy Category D.